Future investigations are needed to assess: 1) other organs or body fluids that may contain tau and amyloids after bacterial infection; 2) the longitudinal dissemination and excretion/decay of the tau and amyloids; 3) whether other infections cause release of tau and amyloids; and, 4) whether tau and amyloids can be used as a prognostic biomarker and/or be a target for prevention and/or treatment of chronic critical illness. The gene discussed is MAPT; the disease is bacterial infectious disease.